The SCCS has just published its final Opinion on the safety of Hydroxyapatite in nano form. It was adopted at its plenary meeting on 30-31 March 2021, after the end of the comment period following its initial publication and review by the Scientific Committee.
Background
The Commission services received 17 notifications under Article 16 of the Cosmetics Regulation via the Cosmetic Product Notification Portal (CPNP) for cosmetic products containing Hydroxyapatite (CAS No.1306-06-17 and EC No.215-145-20) in nano form.
The Commission has concerns on the use of Hydroxyapatite in nano form because of the potential for nanoparticles to be absorbed dermally or across a mucous membrane and to enter cells.
The SCCS published its preliminary Opinion in November 2020.
For an exhaustive background information, see the articles
• SCCS: Requests for Opinions on 3 nanos and DHA, CosmeticOBS, 1st July 2019
• Hydroxyapatite, Copper and Colloidal Copper (nanos): Preliminary Opinions of the SCCS, CosmeticOBS, 16 November 2020
This Opinion has been subject to a commenting period of eight weeks after its initial publication (from 9 November 2020 until 4 January 2021). Comments received during this time were considered by the SCCS. For this Opinion, comments received resulted in the changes related to impurities and genotoxicity.
The comments did not result in a change in the conclusion of the Opinion.
The final Opinion
1. In view of the above, and taking into account the scientific data provided, does the SCCS consider the nanomaterial Hydroxyapatite …
